COVID-19Phase 1/2NCT04760730
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)
A Phase 1/2 study testing AZD1222 and rAd26-S in people with COVID-19, run by R-Pharm at 1 site in United Arab Emirates.
Trial summary
This is a Phase I/II, parallel group, single blinded (participant blinded), randomised study assessing the immunogenicity and safety of AZD1222 and rAd26-S administered as heterologous prime-boost in alternating order in 2 study groups for the Prevention of COVID-19. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19
- What is being tested?
- AZD1222 and rAd26-S
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited Arab Emirates
- Study dates
- 13 Jul 2021to 26 Jul 2022
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Participants are:
- Overtly healthy as determined by medical evaluation, or
- Medically stable such that, according to the judgment of the investigator, hospitalisation within the study period is not anticipated and the participant appears likely to be able to remain in follow-up through the end of protocol-specified follow up.
- (A stable medical condition is defined as disease not requiring significant change in therapy or hospitalisation for worsening disease during the 3 months prior to enrolment.)
- Able to understand and comply with study requirements/procedures based on the assessment of the investigator.
Show all 18Show fewer
- Female participants
- Women of childbearing potential must:
- Have a negative pregnancy test on the day of screening and on Day 1
- Use one highly effective form of birth control for at least 28 days prior to Day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of the second dose of study vaccine. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Periodic abstinence, the rhythm method, and withdrawal are NOT acceptable methods of contraception.
- Women are considered of childbearing potential unless they meet either of the following criteria:
- Surgically sterilised (including bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or
- Postmenopausal
- For women aged < 50 years, postmenopausal is defined as having both:
- A history of ≥ 12 months amenorrhea prior to first dosing, without an alternative cause, following cessation of exogenous sex-hormonal treatment, and
- A follicle-stimulating hormone level in the post-menopausal range (Until follicle-stimulating hormone is documented to be within menopausal range, the participant is to be considered of childbearing potential.)
- For women aged ≥ 50 years, postmenopausal is defined as having a history of ≥ 12 months amenorrhea prior to first dosing, without an alternative cause, following cessation of exogenous sex-hormonal treatment.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol of the sudy.
Who cannot join
- Known past laboratory-confirmed SARS-CoV-2 infection less than 6 month prior to screening (the date of diagnosis must be confirmed by an official document).
- Positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) test at screening.
- Significant infection or other illness, including fever > 37.8°C on the day prior to or day of randomisation.
- Any confirmed or suspected immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection; asplenia; recurrent severe infections and use of chronic immunosuppressant medication within the past 6 months (≥ 20 mg/day of prednisone or its equivalent, given daily or on alternate days for ≥ 15 days within 30 days prior to vaccination), except topical/inhaled steroids or short term oral steroids (course lasting ≤ 14 days).
- Note: HIV-positive participants with CD4 counts > 500 for ≥ 12 months and on a stable HIV antiretroviral regimen may be enrolled.
- Note: Topical tacrolimus is allowed if not used within 14 days prior to the day of enrolment.
Show all 29Show fewer
- History of allergy to any component of the vaccine.
- Any history of anaphylaxis or angioedema.
- Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ).
- History of serious psychiatric condition likely to affect participation in the study.
- Bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture.
- Suspected or known current alcohol or drug dependency.
- History of Guillain-Barré syndrome or any other demyelinating condition.
- Any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data.
- (Note: The adverse events of special interest (AESIs) as outlined in Appendix F of the protocol should be considered when evaluating a participant for Exclusion Criterion 13, as the presence of these AESIs, especially if untreated or uncontrolled, may be a safety risk to the participant, affect the ability of the participant to participate in the study or impair interpretation of the study data. Investigators should review and consider the list of conditions in Appendix F. If any of these conditions is present in a participant, the Investigator is asked to utilise his/her clinical judgment in determining the participant's eligibility for the study. Should the participant have conditions as outlined in Appendix F and is enrolled, the Investigator is asked to document notes on site regarding the final rationale for enrolment.)
- Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed).
- Prior splenectomy.
- History of cerebral venous sinus thrombosis or experienced major venous and/or arterial thrombosis.
- Receipt of any vaccine (licensed or investigational) other than the study vaccine within 30 days before and after each study vaccination.
- Prior (less than 12 months) or planned receipt of an investigational or licensed vaccine or product likely to impact on interpretation of the trial data (eg, adenovirus vectored vaccines, any coronavirus vaccines).
- (Note: Participant vaccinated against coronavirus 12 months or more prior to screening could be included.)
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the planned administration of the vaccine candidate.
- Continuous use of anticoagulants, such as coumarins and related anticoagulants (ie, warfarin) or novel oral anticoagulants (ie, apixaban, rivaroxaban, dabigatran and edoxaban).
- Participation in COVID-19 prophylactic drug trials for the duration of the study.
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca/R-Pharm staff and/or staff at the study site).
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
- Previous randomisation in the present study.
- For women only - currently pregnant (confirmed with positive pregnancy test) or breast feeding.
- Unwilling to refrain from blood donation during the course of the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase I/II Single-Blinded Randomised Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID-19
This is a Phase I/II, parallel group, single blinded (participant blinded), randomised study assessing the immunogenicity and safety of AZD1222 and rAd26-S administered as heterologous prime-boost in alternating order in 2 study groups for the Prevention of COVID-19.
Read the detailed description
This is a prospective, single blinded randomised clinical study, designed to provide data on the heterologous prime boost use of AZD1222 and rAd26-S, to be administered one after the other interchangeably. This study aims to explore the immunogenicity and safety of combining these 2 different adenovirus vector vaccines in the prevention of coronavirus disease 2019 (COVID-19).
Participants will be healthy adults ≥ 18 years of age.
Approximately 100 participants will be randomised (1:1) to one of the following groups:
- Group A: 1 intramuscular (IM) injection of 5×10^10 vp (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10^11vp (nominal) on Day 29.
- Group B: 1 IM injection of rAd26-S (1.0±0.5) х 10^11vp (nominal) on Day 1 followed by AZD1222 5×10^10 vp (nominal) on Day 29.
Immunogenicity will be assessed for the duration of the study, including serologic quantification of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antigen specific antibody levels and antibody seroconversion rate, neutralising antibody assays and cellular immunity testing.
Safety will be assessed for the duration of the study as follows:
- Solicited adverse events (AEs) (local and systemic) will be assessed for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination).
- Unsolicited AEs will be recorded for 29 days following each vaccination (ie, until Day 29 following the first vaccination and Day 57 following the second vaccination).
- Serious adverse events (SAEs) will be recorded from signing of the informed consent form through Day 180. However, the safety endpoint for SAEs will be assessed after the first vaccination (see Section 12.2).
- Adverse events of special interest (AESIs) will be recorded from first vaccination through Day 180.
This study is going to be conducted in the United Arab Emirates. All participants will remain on study for 6 months (180 days) following the first vaccination.
- Conditions
- COVID-19
- Being tested
- AZD1222, rAd26-S
- Keywords
- SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, 2019-nCoV, 2019 novel coronavirus, Respiratory disease, lung disease, COVID-19 Pandemic, coronavirus
- Medical subject headings
- COVID-19, Respiration Disorders, Lung Diseases, Coronavirus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AZD1222Biological
Also called ChAdOx1 nCoV-19
Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10^10 particles (nominal) per dose (unit dose strength > 0.7 × 10^11 vp/mL).
Solution for intramuscular injection, supplied in vials in a carton box
rAd26-SBiological
Also called Gam-COVID-Vac combined vector vaccine
Component I (Dose 1) - (0.5 ml per dose) contains:
Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10^11 particles per dose (unit dose strength 1 × 10^11 vp/0.5 mL) .
Solution for intramuscular injection, supplied in vials in containers
| Study group | Role | What they receive |
|---|---|---|
| Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29 | Experimental | Subjects will receive 1 intramuscular (IM) injection of 5 × 10^10 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 29 Receives: Biological: AZD1222; Biological: rAd26-S |
| Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29 | Experimental | Subjects will receive 1 intramuscular (IM) injection of rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 1 followed by AZD1222 5 × 10^10 vp (nominal) on Day 29. Receives: Biological: AZD1222; Biological: rAd26-S |
What is being measured
The primary outcome is the main question the study is designed to answer.
Antibody seroconversion rate (≥ 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination
The proportion of participants with post treatment seroresponse (defined as ≥ 4-fold rise in titres from Day 1 baseline value) to S antigen 29 days post second vaccination.
Measured: Day 57
Secondary outcomes (11)
Incidence of local and systemic solicited Adverse Events (AEs) for 7 days following each vaccination
Number of Participants Reporting local (Pain at the site of injection, Erythema/redness at the site of injection, Tenderness, Induration/swelling at the site of injection) and systemic (Fever > 37.8°C, Chills, Muscle pains, Fatigue, Headache, Malaise, Nausea, Vomiting) Solicited Adverse Events for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination)
Measured: from Day 1 till Day 7 and from Day 29 till Day 35
Incidence of unsolicited AEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) through 29 days post each vaccination
Number of Participants Reporting unsolicited AEs, SAEs and AESIs through 29 days post each vaccination.
Measured: from day 1 till Day 29 and from Day 29 till Day 57
Antibody seroconversion rate (≥ 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post first vaccination
The proportion of participants who have a post treatment seroresponse (defined as: ≥ 4 fold rise in titres from Day 1 baseline value) to the S antigens 29 days post first vaccination.
Measured: Day 29
Antibody seroconversion rate (≥ 4 fold increase from baseline) against Receptor Binding Domain (RBD) antigen
The proportion of participants with post treatment seroresponse (defined as: ≥ 4-fold rise in titres from Day 1 baseline value) to RBD antigen 29 days post each vaccination.
Measured: Day 29, Day 57
Сhange from baseline Geometric Mean Titre (GMT) of immunogenicity against Spike and RBD antigens at Day 15, 29, 57, 180.
Сhange from baseline GMT against S and RBD antigens at at Day 15, 29, 57, 180.
Measured: Day 1, Day 15, Day 29, Day 57, Day 180
Change from baseline Geometric Mean Fold Rise (GMFR) of immunogenicity against Spike and RBD antigens at Day 15, 29, 57, 180.
Change from baseline GMFR against S and RBD antigens at Day 15, 29, 57, 180.
Measured: Day 1, Day 15, Day 29, Day 57, Day 180
Antibody seroconversion rate (≥ 4 fold increase from baseline) SARS-CoV-2 neutralising antibodies 29 days post each vaccination (Day 29 and Day 57)
The proportion of participants with post treatment seroresponse (defined as: ≥ 4-fold rise in titres day from Day 1 baseline value to 29 days post each vaccination - Day 29 and Day 57), as measured by SARS-CoV-2 neutralising antibodies
Measured: Day 29, Day 57
Change from baseline GMT of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at Day 15, 29, 57, 180.
Change from baseline GMT of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at Day 15, 29, 57, 180.
Measured: On Day 1, Day 15, Day 29, Day 57, Day 180
Change from baseline GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at Day 15, 29, 57, 180.
Change from baseline GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at Day 15, 29, 57, 180.
Measured: On Day 1, Day 15, Day 29, Day 57, Day 180
Change from baseline the number of proliferating CD4 and CD8 cells in response to mitogen stimulation and their ratio in trial subjects.
The number of proliferating CD4 and CD8 cells in response to mitogen stimulation and their ratio in trial subjects at Day 1, Day 29 and Day 57.
Measured: Day 1, Day 29, Day 57
Change from baseline Interferon gamma concentration in response to S Ag simulation
Interferon gamma concentration in response to S Ag simulation at Day 1, Day 29 and Day 57.
Measured: Day 1, Day 29, Day 57
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2021
- Study start13 Jul 2021
- Primary completion29 Mar 2022
- Study completion26 Jul 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- R-Pharm
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- AstraZeneca
- Responsible party
- Sponsor
- Investigators
- Mikhail Samsonov, Study director, Chief Medical Officer, R-Pharm
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04760730
- Sponsor's protocol ID
- CV03872091
- Status last verified
- Oct 2022
- First submitted
- 17 Feb 2021
- Last updated
- 26 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I/II Single-Blinded Randomised Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID-19
- ClinicalTrials.gov ID
- NCT04760730
- Acronym / sponsor ID
- CV03872091
- Conditions
- COVID-19
- Keywords
- SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, 2019-nCoV, 2019 novel coronavirus, Respiratory disease, lung disease, COVID-19 Pandemic, coronavirus
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- R-PharmIndustry (pharma, biotech, devices)
- Collaborators
- AstraZeneca
- Study start
- 13 Jul 2021 (actual)
- Primary completion
- 29 Mar 2022 (actual)
- Study completion
- 26 Jul 2022 (actual)
- First posted
- 18 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase I/II, parallel group, single blinded (participant blinded), randomised study assessing the immunogenicity and safety of AZD1222 and rAd26-S administered as heterologous prime-boost in alternating order in 2 study groups for the Prevention of COVID-19.
Detailed description
This is a prospective, single blinded randomised clinical study, designed to provide data on the heterologous prime boost use of AZD1222 and rAd26-S, to be administered one after the other interchangeably. This study aims to explore the immunogenicity and safety of combining these 2 different adenovirus vector vaccines in the prevention of coronavirus disease 2019 (COVID-19).
Participants will be healthy adults ≥ 18 years of age.
Approximately 100 participants will be randomised (1:1) to one of the following groups:
- Group A: 1 intramuscular (IM) injection of 5×10^10 vp (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10^11vp (nominal) on Day 29.
- Group B: 1 IM injection of rAd26-S (1.0±0.5) х 10^11vp (nominal) on Day 1 followed by AZD1222 5×10^10 vp (nominal) on Day 29.
Immunogenicity will be assessed for the duration of the study, including serologic quantification of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antigen specific antibody levels and antibody seroconversion rate, neutralising antibody assays and cellular immunity testing.
Safety will be assessed for the duration of the study as follows:
- Solicited adverse events (AEs) (local and systemic) will be assessed for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination).
- Unsolicited AEs will be recorded for 29 days following each vaccination (ie, until Day 29 following the first vaccination and Day 57 following the second vaccination).
- Serious adverse events (SAEs) will be recorded from signing of the informed consent form through Day 180. However, the safety endpoint for SAEs will be assessed after the first vaccination (see Section 12.2).
- Adverse events of special interest (AESIs) will be recorded from first vaccination through Day 180.
This study is going to be conducted in the United Arab Emirates. All participants will remain on study for 6 months (180 days) following the first vaccination.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29 | Experimental | Biological: AZD1222, Biological: rAd26-SSubjects will receive 1 intramuscular (IM) injection of 5 × 10^10 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 29 |
| Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29 | Experimental | Biological: AZD1222, Biological: rAd26-SSubjects will receive 1 intramuscular (IM) injection of rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 1 followed by AZD1222 5 × 10^10 vp (nominal) on Day 29. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Participants are:
- (A stable medical condition is defined as disease not requiring significant change in therapy or hospitalisation for worsening disease during the 3 months prior to enrolment.)
- Able to understand and comply with study requirements/procedures based on the assessment of the investigator.
- Female participants
Key exclusion criteria (29 listed)
- Known past laboratory-confirmed SARS-CoV-2 infection less than 6 month prior to screening (the date of diagnosis must be confirmed by an official document).
- Positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) test at screening.
- Significant infection or other illness, including fever > 37.8°C on the day prior to or day of randomisation.
- Any confirmed or suspected immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection; asplenia; recurrent severe infections and use of chronic immunosuppressant medication within the past 6 months (≥ 20 mg/day of prednisone or its equivalent, given daily or on alternate days for ≥ 15 days within 30 days prior to vaccination), except topical/inhaled steroids or short term oral steroids (course lasting ≤ 14 days).
- History of allergy to any component of the vaccine.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AZD1222Also: ChAdOx1 nCoV-19Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10^10 particles (nominal) per dose (unit dose strength > 0.7 × 10^11 vp/mL). Solution for intramuscular injection, supplied in vials in a carton box | Biological | Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29, Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29 |
| rAd26-SAlso: Gam-COVID-Vac combined vector vaccineComponent I (Dose 1) - (0.5 ml per dose) contains: Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10^11 particles per dose (unit dose strength 1 × 10^11 vp/0.5 mL) . Solution for intramuscular injection, supplied in vials in containers | Biological | Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29, Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29 |
Primary outcome
Antibody seroconversion rate (≥ 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination
Time frame: Day 57
The proportion of participants with post treatment seroresponse (defined as ≥ 4-fold rise in titres from Day 1 baseline value) to S antigen 29 days post second vaccination.
11 secondary outcomes
Incidence of local and systemic solicited Adverse Events (AEs) for 7 days following each vaccination
Time frame: from Day 1 till Day 7 and from Day 29 till Day 35
Incidence of unsolicited AEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) through 29 days post each vaccination
Time frame: from day 1 till Day 29 and from Day 29 till Day 57
Antibody seroconversion rate (≥ 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post first vaccination
Time frame: Day 29
Antibody seroconversion rate (≥ 4 fold increase from baseline) against Receptor Binding Domain (RBD) antigen
Time frame: Day 29, Day 57
Сhange from baseline Geometric Mean Titre (GMT) of immunogenicity against Spike and RBD antigens at Day 15, 29, 57, 180.
Time frame: Day 1, Day 15, Day 29, Day 57, Day 180
Change from baseline Geometric Mean Fold Rise (GMFR) of immunogenicity against Spike and RBD antigens at Day 15, 29, 57, 180.
Time frame: Day 1, Day 15, Day 29, Day 57, Day 180
Antibody seroconversion rate (≥ 4 fold increase from baseline) SARS-CoV-2 neutralising antibodies 29 days post each vaccination (Day 29 and Day 57)
Time frame: Day 29, Day 57
Change from baseline GMT of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at Day 15, 29, 57, 180.
Time frame: On Day 1, Day 15, Day 29, Day 57, Day 180
Change from baseline GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at Day 15, 29, 57, 180.
Time frame: On Day 1, Day 15, Day 29, Day 57, Day 180
Change from baseline the number of proliferating CD4 and CD8 cells in response to mitogen stimulation and their ratio in trial subjects.
Time frame: Day 1, Day 29, Day 57
Change from baseline Interferon gamma concentration in response to S Ag simulation
Time frame: Day 1, Day 29, Day 57
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2022.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mikhail Samsonov study director
Chief Medical Officer, R-Pharm
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing AZD1222 and rAd26-S in people with COVID-19, run by R-Pharm at 1 site in United Arab Emirates.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antibody seroconversion rate (≥ 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination (time frame: Day 57). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2022.